Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science.
Stemirna Therapeutics specializes in the research and development of mRNA cancer individualized vaccines and miRNA-targeted cancer stem cells.
Stemirna Therapeutics was founded in 2016 by a group of Chinese scholars in Shanghai’s Zhangjiang Drug Valley. The company is headquartered in Shanghai, China.
Stemirna’s pipeline focuses on the development of immuno-oncology and infectious disease vaccines.
Stemirna, by utilizing its mRNA synthesis platform and LPP (lipopolyplex) nano-delivery platform, has co-developed a COVID-19 mRNA vaccine candidate with China’s Tongji University, and a personalized cancer vaccine candidate.
Stemirna is backed by Sequoia Capital China, WuXi AppTec, OrbiMed, China Merchants Medical, Healthcare Industry Equity Fund, Efund, and others. The company raised $188M in Series B round on Jun 04, 2021. This brings Stemirna's total funding to $205M to date.